Emerging cell and molecular targets for treating mucus hypersecretion in asthma

Jaramillo, Ana M.; Vladar, Eszter K.; Holguin, Fernando; Dickey, Burton F.; Evans, Christopher M.

doi:10.1016/j.alit.2024.04.002

Allergology International

2024

DOI: 10.1016/j.alit.2024.04.002

|View full text |Cite

Emerging cell and molecular targets for treating mucus hypersecretion in asthma

Ana M. Jaramillo,

Eszter K. Vladar,

Fernando Holguin

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mucus plugs in severe asthma and related airway diseases

Asano

2024

Allergology International

View full text Add to dashboard Cite

Mucus plugs in severe asthma and related airway diseases

Asano

2024

Allergology International

View full text Add to dashboard Cite

Breaking up Mucus Plugs in Asthma

Busse,

Jarjour

2024

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs

Lombardi,

Cottini,

Bosi

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

Several endotypes of severe asthma with predominantly type 2 inflammation can be distinguished by the immune pathways driving the inflammatory processes. However, in the absence of type 2 inflammation, asthma is less clearly defined and is generally associated with poor responses to conventional anti-asthmatic therapies. Studies have shown that disruption of the epithelial barrier triggers inflammatory responses and increases epithelial permeability. A key aspect of this process is that epithelial cells release alarmin cytokines, including interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP), in response to allergens and infections. Among these cytokines, TSLP has been identified as a potential therapeutic target for severe asthma, leading to the development of a new biologic, tezepelumab (TZP). By blocking TSLP, TZP may produce wide-ranging effects. Based on positive clinical trial results, TZP appears to offer a promising, safe, and effective treatment approach. This narrative review examines the evidence for treating severe asthma with TZP, analyses clinical trial findings, and provides clinicians with practical insights into identifying patients who may respond best to this novel biologic therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Emerging cell and molecular targets for treating mucus hypersecretion in asthma

Cited by 4 publications

References 163 publications

Mucus plugs in severe asthma and related airway diseases

Mucus plugs in severe asthma and related airway diseases

Breaking up Mucus Plugs in Asthma

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs

Contact Info

Product

Resources

About